ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Like most proliferating tumors, GBM relies heavily on accurate DNA repair for maintenance of genome stability. Dysfunction in repair of both single and double strand DNA breaks by PARP inhibition and impairment of homologous recombination, respectively, would be synthetically lethal. In...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Arrillaga-Romany, Isabel, Sahebjam, Solmaz, Picconi, David, Campian, Jian, Giglio, Pierre, Drappatz, Jan, Aiken, Robert, Villano, John, Lee, Eudocia, Welch, Mary, Ellingson, Benjamin, Ney, Douglas, Becker, Kevin, Muzikansky, Alona, Das, Biswajit, Swisher, Elizabeth, Nixon, Andrew, Karlovich, Chris, Mickey Williams, P, Percy Ivy, S, Batchelor, Tracy, Gerstner, Elizabeth
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Adult Clinical Trials - Non-Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847111/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky